Texto: 
- bcva: 20/20 -2 ou   (low myope ou)

- color vision (pip): 10/14 od  11/14 os

- red desaturation: 90% od

- white light brightness: 75% od

- pupils: 4->3mm ou,    2+ apd od

- motility: fd & v ou

- visual fields: gross defect to confrontation 7-9 clock hours od; full os

- iop: 16 ou

- sle: normal anterior segment ou

- dfe: 
     lens/vitreous: clear ou 
     macula: +flr, flat and unremarkable ou
     a/v:
        normal caliber w/o nicking, tortuosity,                     
        attenuation, or sheathing ou
     periphery: 
        flat and unremarkable ou
     disc: 
        0.1 c/d ou w/o pallor/heme
        slightly increased fullness/elevation od, but      
        sharp disc margins/clearly-defined vessels
        single flat, hypopigmented lesion just inferior   
        to disc margin od (1/5 dd)
- trans-sphenoidal surgical debulking (uncomplicated)

- serology:
     bartonella
     lyme
     rpr/fta

- mri orbits
presumably new-onset, painless, diffuse r monocular field loss  w/ +apd and subtle abnormalities of r optic disc
large intrasellar and suprasellar mass lesion
pituitary macroadenoma - null cell (non-secreting)
-optic nerve disease:
     neuropathy: compressive/infiltrative,     
     inflammatory, ischemic, toxic
     optic nerve drusen

- retrobulbar optic neuritis 

- neuroretinitis (bartonella, syphilis, lyme)

-intracranial process:
     - mass (pit adenoma, meningioma, glioma,      
     craniopharygioma)
     - aneurysm (most likely ica)
     inflammation (sarcoid, ms)

- retinal dystrophy/degeneration:
     - fundus flavimaculatus
21 y.o. woman reservist, activated & deployed into iraq in march.

air evacuated to germany and then subsequently to wramc in mid july for dyspnea.

pulmonology evaluation made a diagnosis of asthma, and she was started on po steroid burst w/ taper, albuterol, advair and singulaire.  

r-sided visual loss (od) started shortly after initiating these asthma meds and remained stable over next 1-2 weeks.  she then reported “i can’t see person standing to my right”. 

she denied any sudden onset - but is unable to pinpoint the moment when her symptoms began nor recall what she was doing; no “falling curtain”.

- no central vision loss ou

- no vision changes os

- no floaters, photopsia or amaurosis 

- no headache, eye pain or photophobia 

- no gross neurologic symptoms (diplopia, dysarthria, weakness, parasthesias, confusion)

- pmh/psh: 
     recent asthma dx

- fh: 
     non-contributory

- social hx:
     no tobacco/rare etoh
     1 previous sexual partner 2 years ago

- meds:
     po prednisone taper (currently 20mg qd)
     albuterol
     singular
     advair
     ocp 

-allergies: 
     pcn
- 10-15% of all intracranial tumors
- normal volunteers had 10% incidence of asymptomatic adenomas by mri

- found in 1.5-27% of autopsy cases

patients present with either:
     hormonal abnormalities
     symptoms of compressive lesion: headache, field    
     defects or cranial nerve palsies (cavernous sinus  
     invasion) 

genetic association:
     men type 1: 
          30% of patients have pit adenoma
          triad with parathyroid and pancreatic islet           
          tumors
     gsp:
          gene that encodes alpha-subunit of     
          gtp-binding protein gs
          mutation leads to activation of camp
     present in:
          40% of gh-secretors
          10% of null cell (non-secretors)
          6% of acth-secretors

classification:
     based on size:
          macroadenoma > 1cm
          microadenoma < 1cm
     based on what the tumor secretes:
          prolactin, gonadotropin, gh, acth, tsh
          nothin’ (null cell)

surgery:
     for most non-prolactin secreting adenomas
     usually trans-sphenoidal:
          mortality <1%
          common complications: nasal septal            
          perforation, ant. pit insufficiency,  
          transient diabetes insipidus, csf leak
          carotid injury and vision loss are rare

     success measures clinically and radiographically
     normalization of hormones varies with type/size of   
     tumor
     normalization of visual fields = 16-53%
     improvement of visual fields = 26-70%

treatment of prolactinomas:
     medical (dopamine agonists)
     - prl secretion inhibited by dopamine secretion  
     from the hypothalamus

     - decreases tumor size      (70-90% of cases)
     - normalizes prl levels     (70-90% of cases)
     - restores ovulation/menses (70-90% of cases)
     - improves visual fields    (70-90% of cases)

     "reversible, therefore lifelong tx is rule"

drugs:
     bromocriptine (classic—used for decades)
     side effects: n/v, dizziness, postural    
     hypotension, ha’s

newer agents:
     lisuride
     pergolide
     cabergoline

new txs for non-prl adenomas:
     gh-secretors:
          somatostatin analogs: octreotide & lanreotide
          reduce gh levels in 90% of pts 
          achieve complete suppression in 50% of pts

radiation:
     usually reserved for residual dz or recurrence   
     after surgery
     average total dose = 45-50 gy
     control rates of 85-95% @ 10 years

3 types:
     standard
     stereotactic fractionated
     stereotactic radiosurgery (single dose / gamma     
     knife)

disadvantages:
      slower reversal of neurologic symptoms
      slower drop in hormonal levels
      hypopituitarism: 50% of pts will have at least     
      one pit hormone deficiency @ 5 yrs       lifelong   
      follow-up
secondary brain tumor:
      risk of 1.3-1.7% @ 10 yrs
      risk of 1.9-2.7% @ 20 yrs
      (relative risk of 9.3-16 x general population)
      radiation-induced optic neuropathy/retinopathy
      low risk: 0.7-2%

srs(stereotactic radiosurgery)
       quicker drop in hormone levels
       adverse cns effects in 28% of cases at 3 yrs    
       compared with 0% with fsrt3

       "not recommended !!"


Keywords by value: 
- ou: 0.4209889482193316
- od: 0.24080320061060936
- of: 0.1518692392938945
- pit: 0.14885518247933321
- gh: 0.14275181432869413
- prl: 0.12410703571764534
- 90: 0.12402300446951964
- yrs: 0.11518325118936057
- optic: 0.11133879396989461
- visual: 0.11035280754087626
- null: 0.10916099889179097
- cases: 0.10439473799386637
- fields: 0.10177909953027103
- pts: 0.09347940623016777
- stereotactic: 0.09211782392066621
- 10: 0.09075873935593869
- adenomas: 0.09030120022897851
- disc: 0.08989569045439827
- vision: 0.08961661891914184
- os: 0.08236780466665308
- levels: 0.08203244486078222
- flat: 0.080315939338542
- dopamine: 0.0790605988154648
- asthma: 0.07738946324267296
- apd: 0.07645142425749274
- bartonella: 0.07442759123966661
- risk: 0.07393346706702503
- advair: 0.07277399926119399
- taper: 0.07016482470322193
- normalization: 0.07016482470322193
- lifelong: 0.06909657426489521
- slower: 0.06909657426489521
- acth: 0.06727656209427878
- radiosurgery: 0.06648739970692316
- secretion: 0.06576144068336255
- albuterol: 0.06446356668909702
- secreting: 0.06446356668909702
- hormonal: 0.06387822514895111
- prolactin: 0.06387822514895111
- loss: 0.06303961792413744
- she: 0.06159508407903232
- 16: 0.06047225647710139
- macroadenoma: 0.05983055911329881
- no: 0.05888449307330335
- and: 0.05879899785255657
- in: 0.057916697689790644
- lyme: 0.05677887503797927
- symptoms: 0.05661463072702727
- neuropathy: 0.056523375156353584
- meds: 0.056523375156353584
- compressive: 0.05627487615967681
- drop: 0.05627487615967681
- nerve: 0.055362891867016636
- 1cm: 0.05491186977776872
- 50: 0.054197270666445745
- tumor: 0.05412244606214719
- effects: 0.05372719096265974
- po: 0.053015481189478665
- hormone: 0.05267952996791099
- size: 0.052546220649335486
- 20: 0.050065832681626565
- what: 0.049746405044903554
- field: 0.0486252702234979
- dose: 0.04831428046534438
- gross: 0.045911243098867634
- to: 0.045269135014176905
- or: 0.04499557065922045
- cell: 0.04439354461779266
- started: 0.04357993500845841
- intracranial: 0.04162895094454571
- myope: 0.04136901190588178
- nicking: 0.04136901190588178
- sheathing: 0.04136901190588178
- neuroretinitis: 0.04136901190588178
- flavimaculatus: 0.04136901190588178
- reservist: 0.04136901190588178
- singulaire: 0.04136901190588178
- curtain: 0.04136901190588178
- floaters: 0.04136901190588178
- photopsia: 0.04136901190588178
- amaurosis: 0.04136901190588178
- pcn: 0.04136901190588178
- volunteers: 0.04136901190588178
- gsp: 0.04136901190588178
- secretes: 0.04136901190588178
- nothin: 0.04136901190588178
- restores: 0.04136901190588178
- lisuride: 0.04136901190588178
- pergolide: 0.04136901190588178
- cabergoline: 0.04136901190588178
- txs: 0.04136901190588178
- lanreotide: 0.04136901190588178
- fractionated: 0.04136901190588178
- srs: 0.04136901190588178
- fsrt3: 0.04136901190588178
- neurologic: 0.04134100148983988
- adenoma: 0.041247014679843715
- single: 0.03978238049433397
- bcva: 0.0395302994077324
- brightness: 0.0395302994077324
- dfe: 0.0395302994077324
- monocular: 0.0395302994077324
- craniopharygioma: 0.0395302994077324
- encodes: 0.0395302994077324
- prolactinomas: 0.0395302994077324
- inhibited: 0.0395302994077324
- normalizes: 0.0395302994077324
- for: 0.039202386297311716
- rare: 0.03905642147077336
- fd: 0.03822571212874637
- macula: 0.03822571212874637
- pinpoint: 0.03822571212874637
- partner: 0.03822571212874637
- singular: 0.03822571212874637
- ant: 0.03822571212874637
- disadvantages: 0.03822571212874637
- quicker: 0.03822571212874637
- tumors: 0.03804957713025871
- abnormalities: 0.037476566857819325
- based: 0.037476566857819325
- confrontation: 0.037213795619833304
- activated: 0.037213795619833304
- moment: 0.037213795619833304
- ocp: 0.037213795619833304
- somatostatin: 0.037213795619833304
- analogs: 0.037213795619833304
- lesion: 0.037205487244791745
- then: 0.03662336207754227
- dd: 0.036386999630596994
- initiating: 0.036386999630596994
- 20mg: 0.036386999630596994
- gs: 0.036386999630596994
- hypopituitarism: 0.036386999630596994
- new: 0.035792178089141494
- drusen: 0.03568795358217353
- camp: 0.03568795358217353
- insipidus: 0.03568795358217353
- agonists: 0.03568795358217353
- bromocriptine: 0.03568795358217353
- achieve: 0.03568795358217353
- headache: 0.03566497199268037
- iop: 0.03508241235161096
- hypopigmented: 0.03508241235161096
- germany: 0.03508241235161096
- parasthesias: 0.03508241235161096
- activation: 0.03508241235161096
- gonadotropin: 0.03508241235161096
- gy: 0.03508241235161096
- type: 0.03470686340118828
- unremarkable: 0.03468416089621554
- desaturation: 0.034548287132447605
- retrobulbar: 0.034548287132447605
- pulmonology: 0.034548287132447605
- palsies: 0.034548287132447605
- hormones: 0.034548287132447605
- radiation: 0.03428494332741876
- serology: 0.03407049584269789
- intrasellar: 0.03407049584269789
- burst: 0.03407049584269789
- microadenoma: 0.03407049584269789
- newer: 0.03407049584269789
- octreotide: 0.03407049584269789
- fh: 0.03363828104713939
- sexual: 0.03363828104713939
- wramc: 0.03324369985346158
- improves: 0.03324369985346158
- onset: 0.03322151588628148
- tortuosity: 0.032880720341681276
- iraq: 0.032880720341681276
- recall: 0.032880720341681276
- usually: 0.03257008189995831
- motility: 0.03223178334454851
- islet: 0.03223178334454851
- dz: 0.03223178334454851
- adverse: 0.03223178334454851
- years: 0.031713819482739436
- normal: 0.03168553630420748
- debulking: 0.03166419064506573
- autopsy: 0.03166419064506573
- hypothalamus: 0.0314049873553122
- dysarthria: 0.031159802076722594
- clock: 0.03092719606556248
- decreases: 0.030705941306888737
- postural: 0.030705941306888737
- triad: 0.03049498127000398
- suppression: 0.03049498127000398
- pip: 0.030293400394684967
- syphilis: 0.030293400394684967
- retinal: 0.030293400394684967
- my: 0.030293400394684967
- gene: 0.030293400394684967
- presumably: 0.03010040007632617
- ha: 0.03010040007632617
- reserved: 0.03010040007632617
- deployed: 0.029915279556649407
- evacuated: 0.029915279556649407
- qd: 0.029915279556649407
- reversible: 0.029915279556649407
- etoh: 0.02973742056454587
- varies: 0.02973742056454587
- low: 0.029686718712760844
- march: 0.02940135402790271
- july: 0.02940135402790271
- reversal: 0.02940135402790271
- orbits: 0.029242221103704637
- person: 0.029242221103704637
- decades: 0.029242221103704637
- patients: 0.029104644924767383
- dx: 0.029088483567413097
- mutation: 0.029088483567413097
- 3mm: 0.02893978752469306
- neuritis: 0.028795812797340142
- knife: 0.028656268771854593
- parathyroid: 0.028389437518989636
- tx: 0.028389437518989636
- photophobia: 0.028261687578176792
- success: 0.028016502299587184
- hypotension: 0.028016502299587184
- gamma: 0.027898708066396487
- surgery: 0.027815763324407276
- confusion: 0.027671919660909802
- leak: 0.027671919660909802
- sle: 0.02745593488888436
- doing: 0.02745593488888436
- prednisone: 0.027249771069263715
- caliber: 0.027150100617549557
- ica: 0.02705257378346004
- diplopia: 0.02705257378346004
- agents: 0.02705257378346004
- average: 0.02695710029919076
- rates: 0.02695710029919076
- most: 0.0269252729010107
- fundus: 0.02686359548132987
- social: 0.02686359548132987
- classification: 0.02659412078741046
- mri: 0.026556959727750306
- present: 0.026547709705529842
- shortly: 0.026507740594739333
- toxic: 0.026422975080027406
- falling: 0.026339764983955495
- men: 0.026339764983955495
- reduce: 0.026339764983955495
- uncomplicated: 0.0262580542507673
- periphery: 0.026098921326569227
- leads: 0.026098921326569227
- drugs: 0.02587022633160712
- have: 0.02584524995456924
- radiographically: 0.02579648774755765
- pupils: 0.025652513020204732
- but: 0.02558381016441962
- remained: 0.025582204278497386
- genetic: 0.025512968994719182
- sharp: 0.02544477488256776
- mortality: 0.02544477488256776
- transient: 0.02544477488256776
- suprasellar: 0.02537759109079491
- with: 0.025326663521364028
- deficiency: 0.025311388119400174
- dizziness: 0.025246137741854226
- nor: 0.025181812932839
- septal: 0.025181812932839
- ms: 0.02511838780104138
- after: 0.025098253760658194
- tsh: 0.024994138302702994
- steroid: 0.024933267281364614
- insufficiency: 0.024933267281364614
- population: 0.024473651659234954
- perforation: 0.024419341752617917
- red: 0.024365674581881838
- sarcoid: 0.02426020882841985
- next: 0.02415714023267219
- cns: 0.02415714023267219
- standing: 0.024056362240837615
- began: 0.024056362240837615
- types: 0.024056362240837615
- protein: 0.024006800840414146
- standard: 0.024006800840414146
- painless: 0.023957775249408265
- least: 0.02390927400632463
- pituitary: 0.0238612860135387
- diabetes: 0.023628680002378586
- nasal: 0.02358355701316305
- hx: 0.02353887859264553
- residual: 0.02353887859264553
- pancreatic: 0.02345082101027505
- on: 0.02343799411113268
- denied: 0.023364440817603922
- color: 0.023321860007096743
- association: 0.023279675302891996
- invasion: 0.023074444670433923
- relative: 0.022916695791111694
- ischemic: 0.02287810131985554
- therefore: 0.022801884013142277
- dyspnea: 0.02276425041126158
- 75: 0.02268990738562501
- margin: 0.02268990738562501
- improvement: 0.022580629254468538
- cavernous: 0.02243890450136198
- light: 0.02240415472978546
- unable: 0.02240415472978546
- sudden: 0.022369669217583772
- subtle: 0.02230147510543235
- defects: 0.02230147510543235
- incidence: 0.022267758793978923
- control: 0.022102837964718815
- subsequently: 0.02207056150817525
- glioma: 0.02197508802390597
- by: 0.021970344304259197
- carotid: 0.021789967504229204
- clinically: 0.02149729673415625
- 28: 0.0214690422938413
- either: 0.02138532010663898
- segment: 0.021357752708670703
- recurrence: 0.021357752708670703
- total: 0.02119577752615301
- cranial: 0.021143046432002047
- measures: 0.021090921455805742
- compared: 0.020913062463702205
- inflammation: 0.020790160009187927
- general: 0.020765974229189226
- just: 0.020694181336592992
- eye: 0.020694181336592992
- 21: 0.02067050074491994
- recommended: 0.020576995927059045
- rule: 0.020530956719434394
- stable: 0.020462762607282962
- csf: 0.02044025723602764
- full: 0.020221141040468515
- slightly: 0.020178560229961336
- vessels: 0.020073825251297556
- made: 0.019951255006079825
- currently: 0.01987134416297301
- complications: 0.01981232177229841
- attenuation: 0.019792817127174015
- mass: 0.01976198510884314
- hours: 0.019715626786876824
- aneurysm: 0.019696532767086657
- previous: 0.0195466076084896
- at: 0.01954155398430109
- process: 0.01940148088748118
- meningioma: 0.019383662306597046
- 40: 0.019024788565129354
- defect: 0.018975762974123473
- ago: 0.01892726173103984
- weakness: 0.01887927373825391
- clear: 0.01875373428883287
- sinus: 0.018692244221285004
- reported: 0.018631576788040696
- mid: 0.01861653590194537
- complete: 0.0181327421983471
- was: 0.018030703657052692
- side: 0.01787054067840137
- 30: 0.017646860232052516
- asymptomatic: 0.017610629762368726
- inferior: 0.017598616979183742
- recent: 0.01751540688311183
- inflammatory: 0.01749191033831477
- central: 0.017274563225725566
- white: 0.017067158518697945
- air: 0.016920183798071264
- injury: 0.01686882625028279
- found: 0.016737956571205904
- any: 0.016718153819211354
- will: 0.016649517350038605
- medical: 0.01644032700020089
- diffuse: 0.016222613688798505
- her: 0.01616103415671726
- brain: 0.01612621768626811
- see: 0.016091666486741596
- evaluation: 0.01577592860725003
- changes: 0.015633709958861527
- when: 0.015625938195176117
- weeks: 0.015503367949958385
- the: 0.01548497780711866
- likely: 0.015458244960742848
- all: 0.01539877101975808
- secondary: 0.015332782131828529
- one: 0.014810804851889223
- common: 0.01467027796526272
- these: 0.014607813850932896
- anterior: 0.014443336156768712
- over: 0.014383901190649123
- is: 0.014168408675435014
- increased: 0.013988335984164917
- into: 0.01375113254344274
- can: 0.013574854042075946
- woman: 0.013472285013720754
- diagnosis: 0.013409933212815838
- large: 0.012961292579641666
- had: 0.01288852840311658
- surgical: 0.012572828099789114
- treatment: 0.012322434570942275
- that: 0.011225863594235528
- disease: 0.010858585135544305
- from: 0.010273784275007887
- not: 0.010212181761352654
- are: 0.009815835930646093
- pain: 0.009256622714986411
- right: 0.008576405275435543
